Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Diabetologia

• Publication date

  2011-02-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00125-011-2084-xPMID 21359582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin‐induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study

  2009cited by this paper
• Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

  2009cited by this paper
• Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

  2009cited by this paper
• Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

  2009cited by this paper
• Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.

  2009cited by this paper
• Intensive glycemic control and the prevention of cardiovascular events:implications of the ACCORD,ADVANCE,and VA Diabetes Trials

  2009cited by this paper
• New Users of Metformin Are at Low Risk of Incident Cancer

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

  2009cited by this paper
• Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?

  2009cited by this paper
• The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

  2009cited by this paper
• Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

  2009cited by this paper
• Effect of a multifactorial intervention on mortality in type 2 diabetes.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart

  2008cited by this paper
• Cancer as an endocrine problem.

  2008cited by this paper
• Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes

  2008cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.

  2007cited by this paper
• The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

  2007influential reference
• Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

  2007cited by this paper
• The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas.

  2007cited by this paper
• Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).

  2007cited by this paper
• Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

  2006cited by this paper
• Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission

  2006cited by this paper
• Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

  2006cited by this paper
• Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

  2006cited by this paper
• AMP‐activated protein kinase: role in metabolism and therapeutic implications

  2006cited by this paper
• Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.

  2005influential reference
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

  2003cited by this paper
• Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.

  2003cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• The association between cardiac events and myocardial ischaemia following thrombolysis in acute myocardial infarction and the impact of carvedilol.

  1996cited by this paper
• Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.

  1996cited by this paper
• Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.

  1995influential reference
• [Paget's disease of the mandible].

  1971cited by this paper

• The role of stress-induced hyperglycemia in acute coronary syndromes: pathophysiology, novel markers and clinical implications

  2025cites this paper
• Effects of metformin treatment on the risk of acute myocardial infarction

  2025cites this paper
• Investigation of Anti-inflammatory, Antioxidative, and Cardioprotective Effects of Combined Metformin and Exercise in Rats

  2024cites this paper
• Impact of stress hyperglycemia ratio, derived from glycated albumin or hemoglobin A1c, on mortality among ST-segment elevation myocardial infarction patients

  2023cites this paper
• Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease.

  2023cites this paper
• Low glucose metabolizing capacity and not insulin resistance is primary etiology of Type 2 Diabetes Mellitus: A hypothesis

  2022cites this paper
• Impact of glycemic gap on 30-day adverse outcomes in patients with acute ST-segment elevation myocardial infarction.

  2022cites this paper
• The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population

  2022cites this paper
• Effects of continuous use of metformin on cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction

  2021cites this paper
• Impacts of early insulin treatment vs glimepiride in diabetic patients with background metformin therapy

  2021cites this paper
• Nutrient regulation of inflammatory signalling in obesity and vascular disease.

  2021cites this paper
• Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial

  2021cites this paper
• The Prevention and Control of Cancer by Metformin in Patients with Type 2 Diabetes: A Systematic Mapping Review

  2021cites this paper
• Human umbilical cord mesenchymal stem cells-derived exosomes transfers microRNA-19a to protect cardiomyocytes from acute myocardial infarction by targeting SOX6

  2020cites this paper
• Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus

  2020cites this paper
• SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients

  2020cites this paper
• Insulin: too much of a good thing is bad

  2020cites this paper
• Insulin resistance: Unsolved issues of harm and use

  2020cites this paper
• Diabetes pay-for-performance program can reduce all-cause mortality in patients with newly diagnosed type 2 diabetes mellitus

  2020cites this paper
• Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis.

  2019cites this paper
• The association of intravenous insulin and glucose infusion with intensive care unit and hospital mortality: a retrospective study

  2019cites this paper
• Consensus Recommendations for Clinical Practice: Management of Glycemia in a Person with Type 2 Diabetes Mellitus with Heart Failure: An Indian Perspective

  2019cites this paper
• The efficacy of metformin treatment for myocardial infarction: a meta-analysis of randomized controlled trials

  2019cites this paper
• Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study

  2019cites this paper
• Metformin for lung cancer prevention and improved survival: a novel approach.

  2019cites this paper
• Triple and Quadruple Combination Therapy in Type 2 Diabetes: How Rational is the Approach?

  2019cites this paper
• Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis

  2019cites this paper
• Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome

  2019cites this paper
• Mechanisms of action of metformin with special reference to cardiovascular protection

  2019cites this paper
• Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population‐based, propensity‐score‐matched cohort study

  2018cites this paper
• In-Hospital Implementation of Evidence-Based Medications is Associated with Improved Survival in Diabetic Patients with Acute Coronary Syndrome - Data from TSOC ACS-DM Registry.

  2018cites this paper
• Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy

  2018cites this paper
• Effect of metformin on cardiac function in patients with STEMI : a systematic review and meta-analysis

  2018cites this paper
• Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?

  2017cites this paper
• Differential effects of metformin on age related comorbidities in older men with type 2 diabetes.

  2017cites this paper
• Antihyperglycemic agents and cardiovascular outcomes: recent insights

  2017cites this paper
• Pathophysiological Construct of Diabetes and its Complications

  2017cites this paper
• Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT

  2017cites this paper
• Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data.

  2017cites this paper
• Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes.

  2017cites this paper
• Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

  2017cites this paper
• Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus

  2017cites this paper
• The burden of myocardial infarction

  2017cites this paper
• Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials.

  2017cites this paper
• Insulin Therapy Increases Cardiovascular Risk: Time for a Sea of Change in Type 2 Diabetes Treatment

  2017influential citation
• Emerging drugs for the treatment of angina pectoris

  2016cites this paper
• Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus

  2016cites this paper
• The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction

  2016cites this paper
• Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care

  2016cites this paper
• Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials.

  2016influential citation
• Cardiovascular effects of anti-diabetes drugs

  2016cites this paper
• Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile

  2016cites this paper
• Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials.

  2016influential citation
• Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials

  2016cites this paper
• Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)

  2016cites this paper
• [Management of hyperglycemic/diabetic patient during and in the immediate follow-up of an acute coronary syndrome].

  2016cites this paper
• The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial

  2015cites this paper
• The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction

  2015cites this paper
• New forms of insulin and insulin therapies for the treatment of type 2 diabetes.

  2015cites this paper
• Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies

  2015cites this paper
• A study of the descriptive epidemiology and clinical effectiveness of treatment for type 2 diabetes using routine general practice data

  2015cites this paper
• Clinical features and treatment of coronary heart disease in diabetes

  2015cites this paper
• Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes

  2015cites this paper
• Insulinosensibilisateurs (metformine/glitazones) : niveau de preuve et controverse

  2015cites this paper
• The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction

  2015cites this paper
• Effects of Metformin on Breast Cancer Risk and Mortality in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

  2015cites this paper
• Glucose‐lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all‐cause mortality, cardiovascular events and cancer

  2015cites this paper
• Metformin and Myocardial Injury in Patients With Diabetes and ST‐Segment Elevation Myocardial Infarction: A Propensity Score Matched Analysis

  2015cites this paper
• Metformin and preservation of left ventricular function

  2015cites this paper
• Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.

  2015cites this paper
• Impacts of insulin infusion protocol on blood glucose level and outcomes in acute coronary syndrome patients with diabetes mellitus

  2015cites this paper
• The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation

  2015cites this paper
• WITHDRAWN: Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

  2015cites this paper
• Clinical trials comparing basal insulins Glargine versus NPH

  2015cites this paper
• Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial.

  2014cites this paper
• Chronic Metformin Treatment is Associated with Reduced Myocardial Infarct Size in Diabetic Patients with ST-segment Elevation Myocardial Infarction

  2014cites this paper
• Effect ofMetformin on Left Ventricular Function After AcuteMyocardial Infarction in PatientsWithout Diabetes The GIPS-III Randomized Clinical Trial

  2014cites this paper
• The cardiovascular effects of insulin

  2014cites this paper
• Pharmacological Treatment in Patients with Type 2 Diabetes: Benefits and Risks. Epidemiological Studies from the Swedish National Diabetes Register

  2014cites this paper
• Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials

  2014cites this paper
• Hypoglykämie und Herzrhythmusstörungen bei Patienten mit Diabetes Typ 2

  2014cites this paper
• Metformin protects the myocardium against isoproterenol-induced injury in rats through alleviating endoplasmic reticulum stress.

  2014cites this paper
• Glucose as a risk predictor in acute medical emergency admissions.

  2014cites this paper
• Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders

  2014cites this paper
• Metformin and Prostate Cancer among Diabetic Men

  2014cites this paper
• Role of Insulin in the Type 2 Diabetes Therapy: Past, Present and Future

  2013cites this paper
• Sulfonylureas and meglitinides: historical and contemporary issues.

  2013cites this paper
• Kardiovaskuläres Risiko bei Hypoglykämie

  2013cites this paper
• Intensive insulin for type 2 diabetes: the risk of causing harm.

  2013cites this paper
• Divergent effects of various diabetes drugs on cardiovascular prognosis.

  2013cites this paper
• Diabetes ¿Un concepto enfocado en reducción de riesgo cardiovascular?

  2013cites this paper
• Utilisation de la metformine chez le patient diabétique cardiaque : balance bénéfices-risques

  2013cites this paper
• Propofol mediates risk-safe cross-talk in h9c2 myofibroblasts

  2013cites this paper
• Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes.

  2013influential citation
• Coronary artery disease The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes : a report from the DIGAMI 2 trial

  2013cites this paper
• Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes

  2013cites this paper
• Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes

  2013cites this paper
• Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review

  2013cites this paper
• Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial

  2013cites this paper
• Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation

  2012cites this paper